相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Multiple Myeloma, Version 3.2022 Featured Updates to the NCCN Guidelines
Natalie S. Callander et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
Katrina Piedra et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies
Claire Comerford et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)
Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: A prospective cohort study
Zara Sayar et al.
THROMBOSIS RESEARCH (2022)
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel
Valerio De Stefano et al.
HAEMATOLOGICA (2022)
Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma
Kristen M. Sanfilippo et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2022)
Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance
Leanne R. O'Sullivan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
P-180: Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in newly diagnosed Multiple Myeloma (NDMM): analysis of vascular thrombotic events (VTEs) in the GRIFFIN study
Douglas Sborov et al.
Clinical Lymphoma Myeloma & Leukemia (2021)
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study
Fahrettin Covut et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a post hoc analysis of phase 3 clinical trials
Jiasheng Wang et al.
LEUKEMIA & LYMPHOMA (2021)
Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance
Thoger Nielsen et al.
THROMBOSIS RESEARCH (2021)
Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy
Rajshekhar Chakraborty et al.
BLOOD CANCER JOURNAL (2021)
Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients
Aisling Barrett et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
Nigel S. Key et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis
Rajshekhar Chakraborty et al.
CANCER (2020)
Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools
Despina Fotiou et al.
CANCERS (2020)
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials
Charlotte A. Bradbury et al.
BLOOD (2020)
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents
Robert F. Cornell et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Assessing the risk of venous thromboembolism in multiple myeloma
Kristen M. Sanfilippo
THROMBOSIS RESEARCH (2020)
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji K. Kumar et al.
LANCET ONCOLOGY (2020)
D-Dimer Improves Risk Prediction of Venous Thromboembolism in Patients with Multiple Myeloma
Kristen M. Sanfilippo et al.
BLOOD (2020)
Venous thromboembolism in multiple myeloma is associated with increased mortality
Martin W. Schoen et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials
Florian Moik et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel
Valerio De Stefano et al.
HAEMATOLOGICA (2020)
Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens
Neill P. F. Storrar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer
Giancarlo Agnelli
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
A. A. Khorana et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Updates on thrombotic events associated with multiple myeloma
Despina Fotiou et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma
Ang Li et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score
Kristen M. Sanfilippo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
The hypercoagulable state in multiple myeloma: The contribution of thrombin generation test
Hela Baccouche et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2019)
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Marc Carrier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation
Hailey A. Baker et al.
CANCER MEDICINE (2019)
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study
Brigitte Pegourie et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study
Emilie Chalayer et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2019)
Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin use
Giacomo Zoppellaro et al.
SEMINARS IN HEMATOLOGY (2018)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations
Dawn Swan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Thierry Facon et al.
BLOOD (2018)
Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma
Satish Maharaj et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
Jian Hou et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients
Yan-juan Zhu et al.
LUNG CANCER (2017)
Circulating extracellular DNA levels are acutely elevated in ischaemic stroke and associated with innate immune system activation
Grant C. O'Connell et al.
BRAIN INJURY (2017)
Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia
Nabin Khanal et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Safety of anticoagulation in the treatment of venous thromboembolism in patients with haematological malignancies and thrombocytopenia: Report of 5 cases and literature review
Ming Sheng Lim et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review
Fatimah Al-Ani et al.
THROMBOSIS RESEARCH (2016)
Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
A. Rosenthal et al.
BLOOD CANCER JOURNAL (2016)
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
Evangelos Terpos et al.
HAEMATOLOGICA (2015)
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma
Marina A. Gracheva et al.
LEUKEMIA & LYMPHOMA (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
Evangelos Terpos et al.
HAEMATOLOGICA (2015)
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Paul G. Richardson et al.
BLOOD (2014)
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
Paul G. Richardson et al.
BLOOD (2014)
International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2014)
Venous Thromboembolism in Multiple Myeloma
Valerio De Stefano et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2014)
Platelet hyporeactivity in active myeloma
Karl Egan et al.
THROMBOSIS RESEARCH (2014)
Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma
Joanna Rupa-Matysek et al.
THROMBOSIS RESEARCH (2014)
Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
M. A. Dimopoulos et al.
BLOOD CANCER JOURNAL (2014)
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens
Tina Bagratuni et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02
Xavier Leleu et al.
BLOOD (2013)
Efficacy and Safety Profile of Long-Term Exposure to Lenalidomide in Patients With Recurrent Multiple Myeloma
Guillemette Fouquet et al.
CANCER (2013)
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
Jian Hou et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States
Alok A. Khorana et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2013)
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide
Alessandra Larocca et al.
BLOOD (2012)
Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma
Marta Robak et al.
MEDICAL ONCOLOGY (2012)
Circulating tissue factor positive microparticles in patients with acute recurrent deep venous thrombosis
Runyi Ye et al.
THROMBOSIS RESEARCH (2012)
Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance
Antonio Palumbo et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2012)
Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism
Henrik Gregersen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis
M. Carrier et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
M. A. Dimopoulos et al.
LEUKEMIA (2011)
Multiple Myeloma, Venous Thromboembolism, and Treatment-Related Risk of Thrombosis
Elena Zamagni et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2011)
Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma
Johannes J. A. Auwerda et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study
Sigurdur Y. Kristinsson et al.
BLOOD (2010)
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
Jeffrey A. Zonder et al.
BLOOD (2010)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study
Eduard J. Libourel et al.
BLOOD (2010)
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin
Michela Cini et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone
Maurizio Zangari et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes
L. L. Swystun et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
Giancarlo Agnelli et al.
LANCET ONCOLOGY (2009)
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
Sigurdur Y. Kristinsson et al.
BLOOD (2008)
Development and validation of a predictive model for chemotherapy-associated thrombosis
Alok A. Khorana et al.
BLOOD (2008)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients
Maurizio Zangari et al.
BLOOD COAGULATION & FIBRINOLYSIS (2007)
Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis
AMW van Marion et al.
THROMBOSIS AND HAEMOSTASIS (2005)
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study
A Cortelezzi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance
S Sallah et al.
ANNALS OF ONCOLOGY (2004)
分享论文
